LIONVILLE, Pa., Feb. 24, 2011 /PRNewswire/ — West
Pharmaceutical Services, Inc. (NYSE:
WST) today announced that its Board of Directors increased the
size of the Board to twelve and appointed two new directors, Mr.
Mark A. Buthman and Mr. Douglas A. Michels. Each of their terms are
effective immediately and will expire at the 2011 Annual Meeting of
Shareholders, when they will stand for election to serve for the
balance of their terms. The appointments anticipate the August 2011
retirement of directors John P. Neafsey and Geoffrey F.
Worden under the Board’s retirement policy.
Mr. Buthman, 50, is Senior Vice President and Chief Financial
Officer of Kimberly-Clark Corporation (NYSE:
KMB), a global producer of branded products for the consumer,
professional and healthcare markets. Mr. Michels, 54, is
President, Chief Executive Officer and a member of the board of
directors of Orasure Technologies, Inc. (Nasdaq:
OSUR), a clinical diagnostic-products company based in
“We are pleased to welcome two highly qualified corporate
executives to our diverse and independent board,” said Donald E.
Morel, Jr., Ph.D., West’s Chairman and Chief Executive Officer in
announcing the appointments. “Their unique backgrounds will
help to maintain an important balance of operational, financial and
healthcare expertise on the Board. We appreciate the substantial
commitments that our directors make to the Company and its
shareholders, and our continued ability to attract strong and
talented independent directors reflects well on our Company and its
The Board also approved payment of the second-quarter 2011 cash
dividend of $0.17 per share. The dividend will be paid on May 4,